Epigenetic changes in Alzheimer's disease: Decrements in DNA methylation

Abstract

DNA methylation is a vital component of the epigenetic machinery that orchestrates changes in multiple genes and helps regulate gene expression in all known vertebrates. We evaluated immunoreactivity for two markers of DNA methylation and eight methylation maintenance factors in entorhinal cortex layer II, a region exhibiting substantial Alzheimer's disease (AD) pathology in which expression changes have been reported for a wide variety of genes. We show, for the first time, neuronal immunoreactivity for all 10 of the epigenetic markers and factors, with highly significant decrements in AD cases. These decrements were particularly marked in PHF1/PS396 immunoreactive, neurofibrillary tangle-bearing neurons. In addition, two of the DNA methylation maintenance factors, DNMT1 and MBD2, have been reported also to interact with ribosomal RNAs and ribosome synthesis. Consistent with these findings, DNMT1 and MBD2, as well as p66α, exhibited punctate cytoplasmic immunoreactivity that co-localized with the ribosome markers RPL26 and 5.8s rRNA in ND neurons. By contrast, AD neurons generally lacked such staining, and there was a qualitative decrease in RPL26 and 5.8s rRNA immunoreactivity. Collectively, these findings suggest epigenetic dysfunction in AD-vulnerable neurons.

Urine Formaldehyde: A Non-Invasive Marker for Alzheimer’s Disease?

“…During aging, a decrease in global hippocampal 5-mC level [32] and an increase in 5hmC content have been observed in hippocampus [33]. Consistently, a wide global DNA demethylation associated with an abnormal high level of formaldehyde was found in autopsy samples from AD patients [34][35][36]. 2) Tumor.…”

Alzforum News Highlights: Caffeine, Anesthesia, and Twin Epigenetics

“…In an earlier study [25], first author Diego Mastroeni and colleagues found lower levels of DNA methylation, as well as reduced expression of DNA methyltransferase and other methylation regulators, in affected brain areas of sporadic AD patients. "This led to the question of whether these epigenetic effects we saw in AD were related to the [people's] genes or to their life experience," said Coleman, who is also a professor emeritus at the University of Rochester Medical Center, New York.…”

Epigenética e doenças humanas

“…Como exemplo, foi observado que há uma diminuição no nível de metilação especificamente na camada II do córtex entorrinal, principal região afetada pela patologia de Alzheimer, e essa diminuição relacionada à mudança de expressão em vários genes (MASTROENI et al, 2010). Já na doença de Parkinson, encontrou-se na substância negra do cérebro uma diminuição de metilação do promotor do gene TNF-α, uma citocina chave no processo inflamatório envolvido na doença (PIEPER et al,2008).…”